WOC
LSTA icon

West Oak Capital’s Lisata Therapeutics LSTA Stock Holding History

West Oak Capital’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7
Closed -$356 – 318
2018
Q4 		$356 Hold
7
– – ﹤0.01% 329
2018
Q3 		$590 Hold
7
– – ﹤0.01% 353
2018
Q2 		$647 Hold
7
– – ﹤0.01% 320
2018
Q1 		$584 Buy
+7
New +$485 ﹤0.01% 335

Other funds holding LSTA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $616M AUM 18.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

West Oak Capital's LSTA Position: Q1 2019 in Review

West Oak Capital sold out of Lisata Therapeutics (LSTA) in Q1 2019, closing a stake of 7 shares — an estimated $356 sold.

West Oak Capital first reported a position in LSTA in Q1 2018 and held it in 4 quarters. The position peaked at $647 in Q2 2018. 28 funds tracked by Wall St. Rank hold LSTA as of Q1 2019.

  • West Oak Capital reported no remaining Lisata Therapeutics position as of Q1 2019 after selling out during the quarter.
  • West Oak Capital sold 7 Lisata Therapeutics shares in Q1 2019, an estimated $356.
  • West Oak Capital first reported a position in Lisata Therapeutics in Q1 2018 and held it in 4 quarters.
  • West Oak Capital's Lisata Therapeutics position peaked at $647 in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2019.

Based on West Oak Capital's 13F filing for Q1 2019, filed 3 Apr 2019.